Your browser doesn't support javascript.
loading
GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant.
Liu, Ilon; Alencastro Veiga Cruzeiro, Gustavo; Bjerke, Lynn; Rogers, Rebecca F; Grabovska, Yura; Beck, Alexander; Mackay, Alan; Barron, Tara; Hack, Olivia A; Quezada, Michael A; Molinari, Valeria; Shaw, McKenzie L; Perez-Somarriba, Marta; Temelso, Sara; Raynaud, Florence; Ruddle, Ruth; Panditharatna, Eshini; Englinger, Bernhard; Mire, Hafsa M; Jiang, Li; Nascimento, Andrezza; LaBelle, Jenna; Haase, Rebecca; Rozowsky, Jacob; Neyazi, Sina; Baumgartner, Alicia-Christina; Castellani, Sophia; Hoffman, Samantha E; Cameron, Amy; Morrow, Murry; Nguyen, Quang-De; Pericoli, Giulia; Madlener, Sibylle; Mayr, Lisa; Dorfer, Christian; Geyeregger, Rene; Rota, Christopher; Ricken, Gerda; Ligon, Keith L; Alexandrescu, Sanda; Cartaxo, Rodrigo T; Lau, Benison; Uphadhyaya, Santhosh; Koschmann, Carl; Braun, Emelie; Danan-Gotthold, Miri; Hu, Lijuan; Siletti, Kimberly; Sundström, Erik; Hodge, Rebecca.
Afiliação
  • Liu I; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie
  • Alencastro Veiga Cruzeiro G; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Bjerke L; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK.
  • Rogers RF; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK.
  • Grabovska Y; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK.
  • Beck A; Center for Neuropathology, Ludwig-Maximilians-University, 81377 Munich, Germany.
  • Mackay A; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK.
  • Barron T; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Hack OA; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Quezada MA; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Molinari V; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK.
  • Shaw ML; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Perez-Somarriba M; Children & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton, Surrey SM2 5 NG, UK.
  • Temelso S; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK.
  • Raynaud F; Division of Cancer Therapeutics, The Institute of Cancer Research, London SW7 3RK, UK.
  • Ruddle R; Division of Cancer Therapeutics, The Institute of Cancer Research, London SW7 3RK, UK.
  • Panditharatna E; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Englinger B; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria; Center for C
  • Mire HM; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Jiang L; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Nascimento A; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • LaBelle J; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Haase R; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Rozowsky J; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Neyazi S; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Baumgartner AC; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Castellani S; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Hoffman SE; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Cameron A; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Morrow M; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Nguyen QD; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Pericoli G; Department of Onco-haematology, Gene and Cell Therapy, Bambino Gesù Children's Hospital-IRCCS, 00165 Rome, Italy.
  • Madlener S; Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
  • Mayr L; Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
  • Dorfer C; Department of Neurosurgery, Medical University of Vienna, 1090 Vienna, Austria.
  • Geyeregger R; Clinical Cell Biology, Children's Cancer Research Institute (CCRI), Vienna 1090, Austria.
  • Rota C; Department of Neurobiology, Harvard Medical School, Boston, MA 02215, USA.
  • Ricken G; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna 1090, Austria.
  • Ligon KL; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA; Department of Pathology, Boston Children's Hospital, Boston, MA 02115, U
  • Alexandrescu S; Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Cartaxo RT; Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA.
  • Lau B; Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA.
  • Uphadhyaya S; Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA.
  • Koschmann C; Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA.
  • Braun E; Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden.
  • Danan-Gotthold M; Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden.
  • Hu L; Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden.
  • Siletti K; Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden.
  • Sundström E; Division of Neurodegeneration, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, 17177 Stockholm, Sweden.
  • Hodge R; Allen Institute for Brain Science, Seattle, WA 98109, USA.
Cancer Cell ; 2024 Aug 27.
Article em En | MEDLINE | ID: mdl-39232581
ABSTRACT
Diffuse hemispheric gliomas, H3G34R/V-mutant (DHG-H3G34), are lethal brain tumors lacking targeted therapies. They originate from interneuronal precursors; however, leveraging this origin for therapeutic insights remains unexplored. Here, we delineate a cellular hierarchy along the interneuron lineage development continuum, revealing that DHG-H3G34 mirror spatial patterns of progenitor streams surrounding interneuron nests, as seen during human brain development. Integrating these findings with genome-wide CRISPR-Cas9 screens identifies genes upregulated in interneuron lineage progenitors as major dependencies. Among these, CDK6 emerges as a targetable vulnerability DHG-H3G34 tumor cells show enhanced sensitivity to CDK4/6 inhibitors and a CDK6-specific degrader, promoting a shift toward more mature interneuron-like states, reducing tumor growth, and prolonging xenograft survival. Notably, a patient with progressive DHG-H3G34 treated with a CDK4/6 inhibitor achieved 17 months of stable disease. This study underscores interneuronal progenitor-like states, organized in characteristic niches, as a distinct vulnerability in DHG-H3G34, highlighting CDK6 as a promising clinically actionable target.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article